UBS Group
BCRX icon

UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,200
Closed -$43K – 7637
2015
Q4 		$43K Hold
4,200
– – ﹤0.01% 5945
2015
Q3 		$48K Hold
4,200
– – ﹤0.01% 5874
2015
Q2 		$63K Hold
4,200
– – ﹤0.01% 5798
2015
Q1 		$38K Sell
4,200
-700
-14% -$7.25K ﹤0.01% 6300
2014
Q4 		$60K Buy
+4,900
New +$54.1K ﹤0.01% 6260

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

UBS Group's BCRX Position: Q2 2026 in Review

UBS Group increased its BioCryst Pharmaceuticals (BCRX) stake by 2.7% in Q2 2026, buying an estimated $1.21M and bringing the position to 5,078,280 shares worth $50.8M. The position accounts for 0.01% of the portfolio, ranked #1729.

UBS Group first reported a position in BCRX in Q4 2014 and has held it in 47 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • UBS Group held 5,078,280 shares of BioCryst Pharmaceuticals worth $50.8M as of Q2 2026.
  • UBS Group bought 134,286 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.21M.
  • BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1729 holding.
  • UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.